BR112020018593A2 - Moduladores com base em ciclopentano de sting (estimulador de genes de interferon) - Google Patents

Moduladores com base em ciclopentano de sting (estimulador de genes de interferon) Download PDF

Info

Publication number
BR112020018593A2
BR112020018593A2 BR112020018593-0A BR112020018593A BR112020018593A2 BR 112020018593 A2 BR112020018593 A2 BR 112020018593A2 BR 112020018593 A BR112020018593 A BR 112020018593A BR 112020018593 A2 BR112020018593 A2 BR 112020018593A2
Authority
BR
Brazil
Prior art keywords
compound
fact
cancer
nmr
mhz
Prior art date
Application number
BR112020018593-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Fensome
Ketan S. Gajiwala
Mehran JALAIE
Andreas Maderna
Indrawan James McAlpine
Ryan Patman
Eugene Yuanjin Rui
Martin James Wythes
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BR112020018593A2 publication Critical patent/BR112020018593A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65744Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
BR112020018593-0A 2018-03-15 2019-03-12 Moduladores com base em ciclopentano de sting (estimulador de genes de interferon) BR112020018593A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US62/643,467 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US62/666,204 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US62/742,532 2018-10-08
US201962809990P 2019-02-25 2019-02-25
US62/809,990 2019-02-25
PCT/IB2019/052009 WO2019175776A1 (en) 2018-03-15 2019-03-12 Cyclopentane-based modulators of sting (stimulator of interferon genes)

Publications (1)

Publication Number Publication Date
BR112020018593A2 true BR112020018593A2 (pt) 2020-12-29

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020018593-0A BR112020018593A2 (pt) 2018-03-15 2019-03-12 Moduladores com base em ciclopentano de sting (estimulador de genes de interferon)

Country Status (25)

Country Link
US (4) US10538542B2 (https=)
EP (1) EP3765474B1 (https=)
JP (1) JP7266942B2 (https=)
KR (1) KR20200131878A (https=)
CN (1) CN111918871A (https=)
AU (1) AU2019234043A1 (https=)
BR (1) BR112020018593A2 (https=)
CA (1) CA3093631C (https=)
CL (1) CL2020002352A1 (https=)
CR (1) CR20200382A (https=)
DO (1) DOP2020000160A (https=)
EC (1) ECSP20057847A (https=)
ES (1) ES2923298T3 (https=)
IL (1) IL277278A (https=)
MA (1) MA52012A (https=)
MX (1) MX2020009587A (https=)
NI (1) NI202000058A (https=)
PE (1) PE20210412A1 (https=)
PH (1) PH12020551486A1 (https=)
PY (1) PY1919127A (https=)
RU (1) RU2020130048A (https=)
SG (1) SG11202008102VA (https=)
TW (1) TWI741268B (https=)
UY (1) UY38145A (https=)
WO (1) WO2019175776A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
JP2022550297A (ja) * 2019-09-25 2022-12-01 ファイザー・インク Sting(インターフェロン遺伝子刺激因子)のヘテロ多環式モジュレーター
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
JP2023553069A (ja) * 2020-12-08 2023-12-20 エフ. ホフマン-ラ ロシュ アーゲー ホスホロジチオエートオリゴヌクレオチドの新規合成
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
PE20170198A1 (es) * 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
ES2923298T3 (es) 2022-09-26
UY38145A (es) 2019-10-31
US20190284216A1 (en) 2019-09-19
DOP2020000160A (es) 2020-09-30
CL2020002352A1 (es) 2020-12-18
NI202000058A (es) 2021-01-08
CN111918871A (zh) 2020-11-10
PH12020551486A1 (en) 2021-08-23
JP2021518335A (ja) 2021-08-02
IL277278A (en) 2020-10-29
CA3093631C (en) 2023-01-24
TW201945036A (zh) 2019-12-01
US20200102334A1 (en) 2020-04-02
AU2019234043A1 (en) 2020-09-17
EP3765474A1 (en) 2021-01-20
PE20210412A1 (es) 2021-03-04
KR20200131878A (ko) 2020-11-24
MX2020009587A (es) 2020-10-05
US20230382932A1 (en) 2023-11-30
RU2020130048A3 (https=) 2022-04-15
SG11202008102VA (en) 2020-09-29
RU2020130048A (ru) 2022-04-15
US10968242B2 (en) 2021-04-06
CA3093631A1 (en) 2019-09-19
WO2019175776A1 (en) 2019-09-19
PY1919127A (es) 2020-08-26
US10538542B2 (en) 2020-01-21
EP3765474B1 (en) 2022-06-15
JP7266942B2 (ja) 2023-05-01
US20210230196A1 (en) 2021-07-29
ECSP20057847A (es) 2021-04-29
CR20200382A (es) 2020-12-10
MA52012A (fr) 2021-01-20
TWI741268B (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
CA3093631C (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
TWI774697B (zh) 環二核苷酸化合物
CA3078267C (en) Compositions and methods of modulating the immune response by activating alpha protein kinase 1
EP3728283B1 (en) 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
ES2986866T3 (es) Análogo de dinucleótido cíclico, composición farmacéutica del mismo y aplicación
EP3934757B1 (en) 2'3'-cyclic dinucleotides and prodrugs thereof
KR20230107586A (ko) 다기능성 사이클릭 디뉴클레오티드 및 이의 용도
AU2021306597B2 (en) 3'3' cyclic dinucleotides with an alkenylene
OA19842A (en) Cyclopentane-based modulators of sting (stimulator of interferon genes).
HK40031084A (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
TWI639613B (zh) Hcv聚合酶抑制劑
RU2809547C2 (ru) Новое производное циклического динуклеотида и его конъюгат антитело-лекарственное средство
TWI675664B (zh) Hcv聚合酶抑制劑
HK40079070A (zh) 多功能环二核苷酸及其用途
CA3210844A1 (en) 3'3' cyclic dinucleotides containing isonucleotidic units
CN117015383A (zh) 多功能环二核苷酸及其用途
BR112019006512B1 (pt) Compostos, estereoisômeros substancialmente puros, sal farmaceuticamente aceitável, sal de sódio, composições farmacêuticas, vacina e usos dos referidos compostos
BR102017021041A2 (pt) Compostos de dinucleotídeo cíclico

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 19/213 , A61P 35/00

Ipc: A61K 31/7042 (2006.01), A61P 35/00 (2006.01), C07H

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2765 DE 02-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.